Exclusive: ACR Convergence 2024 | Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions
FocusRheum
Guidance
Drug Updates
- Analgesics
- Biologics/DMARDs
Practice Support
- Billing/Coding
- EMRs
- Facility
- Insurance
- QA/QI
- Technology
- Workforce
Opinion
Career
ACR
Search

Teriparatide to Denosumab Switch Helpful in Osteoporosis

David Douglas | July 16, 2015

Page: 1 2 | Single Page

Share:

Filed under:Biologics/DMARDs Conditions Drug Updates Osteoarthritis and Bone Disorders Tagged with:Amgen bone loss bone mineral density (BMD)denosumab National Institutes of Health (NIH)Osteoporosis osteoporosis treatments teriparatide teriparatide treatment for osteoporosis

Related Articles

Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?

March 1, 2008

Handpicked Reviews of Contemporary Literature

Build Up Bone

June 1, 2007

Current management of osteoporosis

High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

September 9, 2019

NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…

New Treatments Needed to Prevent Fractures in Osteoporosis

June 1, 2014

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

About Us
Meet the Editors
Issue Archives
Contribute
Advertise
Contact Us

Copyright © 2000-2024 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
DEI Statement
Privacy Policy
Terms of Use
Cookie Preferences